Clinical Pearls on CRS and ICANS Management in Multiple Myeloma
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Patient Case 3: Development of CRS on a Non-BCMA Targeted Bispecific Antibody
Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.
Management of ICANS Associated with Bispecific Antibodies in MM
A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.
Patient Case 2: Development of ICANS on a BCMA-Targeted Bispecific Antibody
Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.
Cytokine Release Syndrome Grading and Management Strategies in MM
Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.
Administering Step-up and Treatment Doses of Bispecifics in MM
A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.
Patient Case 1: Development of CRS on a BCMA-Targeted Bispecific Antibody
Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.
Role of Multidisciplinary Care in With MM Receiving Bispecific Antibodies
Shared insight on the respective roles of a multidisciplinary care team involved in the management of multiple myeloma and associated adverse events.
Multiple Myeloma: Role of Bispecifics in an Evolving Treatment Landscape
